Abstract

Gastroesophageal adenocarcinoma (GEA) patients with the microsatellite instability (MSI) subtype emerged as optimal candidates for immunotherapy. To date, immunohistochemistry (IHC) is the gold standard for MSI assessment in formalin-fixed paraffin-embedded (FFPE) specimens. However, IHC, although useful for diagnostic typing, cannot be used to analyze cell-free DNA (cfDNA) in liquid biopsy, a tool that could overcome tumor heterogeneity and enable longitudinal monitoring. In order to find an alternative diagnostic method to IHC, we analyzed 86 retrospective GEAs FFPE samples with multiplex PCR. Moreover, to verify the feasibility of MSI detection in liquid biopsy, cfDNA samples of five patients that resulted in having MSI in a prospective cohort of 35 patients were evaluated by multiplex PCR, real-time PCR and droplet digital PCR (ddPCR). Analysis of FFPE showed 100% concordance between multiplex PCR and IHC (Cohen’s Kappa agreement = 1). On the contrary, only ddPCR was able to detect MSI in cfDNAs of T3/T4 GEA patients. In conclusion, data highlight the molecular analysis as an optimal alternative to IHC for the diagnostic typing and suggest that the ddPCR assay can be considered as the most reliable and promising molecular approach to detect MSI in the cfDNA of GEA patients.

Highlights

  • Gastric and esophageal adenocarcinomas, characterized by similar genetic and epigenetic molecular alterations, are collectively termed gastroesophageal adenocarcinomas (GEAs)

  • In order to test the validity of the microsatellite instability (MSI) molecular analysis to implement the MSI GEA diagnostic typing, we retrospectively selected 86 archival formalin-fixed paraffin-embedded (FFPE) samples from

  • GEA patients; we collected 35 prospective GEA patients to test the feasibility of applying the MSI molecular analysis to cell-free DNA (cfDNA) isolated from plasma

Read more

Summary

Introduction

Gastric and esophageal adenocarcinomas, characterized by similar genetic and epigenetic molecular alterations, are collectively termed gastroesophageal adenocarcinomas (GEAs). Gastric adenocarcinoma (GAC) is the 5th most common cancer and the 2nd leading cause of cancer-related death [1]. Esophageal adenocarcinoma (EADC) is instead the 8th most frequent cancer, and the 6th principle cause of cancer-related death worldwide [2]. A multimodality approach to treatment, surgery alone or in combination with preoperative chemo- or chemo-radiotherapy, is associated with recent improvements in disease outcomes and survival. In patients with operable disease treated with neoadjuvant chemotherapy before surgery, the 5-year overall survival (OS) is 36%. In EADC, the overall prognosis is worse [3]. No validated biomarkers predictive of the treatment response to therapeutic agents are available in GAC.

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call